0001127602-12-009009.txt : 20120301 0001127602-12-009009.hdr.sgml : 20120301 20120301181629 ACCESSION NUMBER: 0001127602-12-009009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120228 FILED AS OF DATE: 20120301 DATE AS OF CHANGE: 20120301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALLOS THERAPEUTICS INC CENTRAL INDEX KEY: 0001097264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541655029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 200 CITY: WESTMINSTER STATE: CO ZIP: 80020 BUSINESS PHONE: 3034266262 MAIL ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 200 CITY: WESTMINSTER STATE: CO ZIP: 80020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BENNETT BRUCE K JR CENTRAL INDEX KEY: 0001237532 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29815 FILM NUMBER: 12659454 MAIL ADDRESS: STREET 1: 11080 CIRCLE POINT RD., STE. 200 CITY: WESTMINSTER STATE: CO ZIP: 80020 4 1 form4.xml PRIMARY DOCUMENT X0304 4 2012-02-28 0001097264 ALLOS THERAPEUTICS INC ALTH 0001237532 BENNETT BRUCE K JR 11080 CIRCLEPOINT ROAD SUITE 200 WESTMINSTER CO 80020 1 VP, Pharmaceutical Operations Common Stock 2012-02-28 4 A 0 43862 0 A 153434 D Common Stock 2012-02-29 4 S 0 3031 1.5252 D 150403 D Common Stock 2012-03-01 4 S 0 3025 1.495 D 147378 D Represents shares of common stock issued as restricted stock units ("RSUs") awarded under the Company's 2008 Equity Incentive Plan (the "Plan"). The RSUs shall vest in a series of eight (8) successive equal semi-annual installments over the four (4)-year period measured from March 18, 2012 (the "Vesting Commencement Date"), subject to Participant's Continuous Service through each such date. These shares are being sold pursuant to a 10b5-1 plan for Mr. Bennett under which a portion of his holdings were sold for tax and estate planning purposes in connection with the delivery of shares covered by restricted stock units which vested on February 28, 2012. The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.52 to $1.54. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.49 to $1.50. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. /s/ David C. Clark, attorney-in-fact for Bruce K. Bennett Jr. 2012-03-01